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Introduction {#sec1}
============

Astrocytes are the most abundant cell type in the CNS, rivaling the diversity of neurons in cellular morphologies, gene expression profiles, developmental origins, physiological properties, functions, and responses to injury and disease ([@bib57]). Within the human brain, astrocytes have a variety of essential functions including glutamate biology, axonal guidance, trophic support, inflammatory response and wound healing, formation of the blood-brain barrier, and neuronal synapse formation, and plasticity ([@bib2], [@bib13], [@bib14]). Although the full contribution of astrocytes to neurological disease remains unresolved, astrocyte cell-autonomous deficits have been implicated in a variety of neurological disorders ([@bib44], [@bib49]). The most significant genetic risk factor for Alzheimer\'s disease (AD), apolipoprotein E4 (*APOE4*), is predominantly synthesized and secreted by astrocytes ([@bib53]). Furthermore, astrocytes derived from human induced pluripotent stem cell (hiPSC)- or mouse-based models of amyotrophic lateral sclerosis ([@bib12], [@bib28], [@bib37]), Rett syndrome ([@bib1]), and Huntington disease ([@bib5]) damage neurons in co-culture or after transplantation.

Evolutionarily, the astrocyte-to-neuron ratio increases from low vertebrates to rodents and to primates ([@bib47]). Human cortical astrocytes are larger, structurally more complex and diverse, and propagate calcium waves 4-fold faster than their rodent counterparts ([@bib34]). Transplantation of human glia into mice enhances activity-dependent plasticity and learning ([@bib3]). Given the unique biology of human astrocytes, it is critical that improved human-specific cell-based systems be established to enable the study of human astrocyte function in health and disease.

Because of their ability to model all of the (known and unknown) genetic risk factors underlying neuropsychiatric disease, hiPSCs are routinely used as a source of various types of neurons and astrocytes for study ([@bib31]). Current hiPSC-based methods for the differentiation of astrocytes typically rely on either a neural progenitor cell (NPC) ([@bib16], [@bib24], [@bib30], [@bib45], [@bib46]) or oligodendrocyte progenitor cell ([@bib21]) intermediate. While it has been widely demonstrated that hiPSCs can be differentiated to functional astrocytes for cell-based models of neuropsychiatric disorders *in vitro* ([@bib16], [@bib30], [@bib45], [@bib46]) or engraftment *in vivo* ([@bib10], [@bib16], [@bib21], [@bib24]), existing methods are slow (up to 6 months) ([@bib21], [@bib24], [@bib46]) and/or require sorting to reduce heterogeneity ([@bib9], [@bib55]). Here, we screened a number of published protocols, along with commercially available media for primary human astrocyte culture, identifying a robust and straightforward differentiation protocol for generating astrocytes from hiPSCs. By co-culture with microglia, we compared the function of primary human fetal astrocytes and hiPSC-astrocytes in assays for neuroinflammatory response, phagocytosis, and spontaneous calcium activity, concluding that hiPSC-astrocytes are highly similar to their primary counterparts. Altogether, our rapid differentiation protocol, co-culture strategy, and scalable phenotypic assays will serve as a robust platform for queries of healthy and diseased human astrocytes.

Results {#sec2}
=======

30-Day Exposure of hiPSC-Derived NPCs to Commercial Astrocyte Media Is Sufficient to Robustly Generate hiPSC-Astrocytes {#sec2.1}
-----------------------------------------------------------------------------------------------------------------------

We first screened 11 different media conditions on forebrain-patterned NPCs ([@bib7], [@bib6]) derived from hiPSCs ([Table 1](#tbl1){ref-type="table"}). The screening conditions, based on recently published hiPSC-astrocyte differentiation protocols ([@bib10], [@bib16], [@bib21], [@bib24], [@bib30], [@bib45], [@bib46]), included different combinations of fibroblast growth factor 2 (FGF2) ([@bib16]), ciliary neurotrophic factor (CNTF), ([@bib24], [@bib46]), bone morphogenetic protein 4 (BMP4) ([@bib17], [@bib21], [@bib46]), fibroblast bovine serum (FBS) ([@bib17], [@bib46]), neuregulin ([@bib38], [@bib46]), insulin ([@bib18]), and ascorbic acid (AA) ([@bib35]), as well as three commercial astrocyte media (ScienCell, Gibco, and Lonza) for the culture of primary human fetal astrocytes ([Table 1](#tbl1){ref-type="table"}). Screening criteria included immunoreactivity for two classical markers of astrocyte identity, S100β and glial fibrillary acidic protein (GFAP) ([@bib27]), astrocyte morphology, survival, replicative ability, and cell line variability ([Table S1](#mmc1){ref-type="supplementary-material"}; [Figure S1](#mmc1){ref-type="supplementary-material"}A). When tested on NPCs, most conditions resulted in limited cell proliferation and expression of neuronal markers ([Table S1](#mmc1){ref-type="supplementary-material"}); however, two commercial media, ScienCell and Lonza, yielded S100β- and GFAP-positive astrocyte-like cells ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1D). These results were confirmed across four representative NPC lines by both flow cytometry and immunocytochemistry by 30 days ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}E--S1G). Culture of NPCs in both media, when combined with low initial seeding density (nearly single cells: 15,000 cells/cm^2^) and minimal serum exposure (1%--2%), resulted in astrocyte morphology within 10 days ([Figure S1](#mmc1){ref-type="supplementary-material"}H); star-shaped astrocyte morphologies were evident within 30 days ([Figure S1](#mmc1){ref-type="supplementary-material"}I). Although ScienCell and Lonza astrocyte media showed equivalent efficiencies ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1D), ScienCell medium was selected owing to its lower cost and relative simplicity.Figure 1Rapid Differentiation of hiPSC-Derived NPCs to Astrocyte-like Identity(A) Representative flow-cytometry analysis of S100β (top) and GFAP (bottom) for four 30-day hiPSC-astrocyte differentiations. Arrows indicate the cells positive for each marker protein. Appropriate secondary-only control is shown in black.(B) Graphs of flow-cytometry analysis across 35 hiPSC-astrocyte differentiations from 26 NPC lines from three independent hiPSC cohorts. S100β (left) and GFAP (right) immunostaining is shown, with primary human fetal astrocytes (positive control) and hiPSCs (negative control).(C) Representative immunofluorescence images of hiPSC-astrocytes stained for astrocyte markers, glutamate transporters GLAST (green), VIMENTIN (green), ALDH1L1 (red), and APOE (green). Scale bars, 100 μm.(D) mRNA levels of astrocyte markers: *S100β*, *GFAP*, *VIM*, *AQU4*, *ACSBG1*, and *APOE* in hiPSC-astrocytes (n = 3 from four different lines) and primary human fetal astrocytes (pAstrocytes; n = 3 from cerebral cortex astrocytes). Primer sequences are listed in [Table S3](#mmc1){ref-type="supplementary-material"}. n, the number of independent experiments.(E) mRNA levels of neuronal markers: *TUJ1*, *MAP2AB*, *RELN*, and *CACNA1C* in hiPSC-astrocytes (n = 3 from four different lines) and pAstrocytes (n = 3 from cerebral cortex astrocytes), relative to h*NGN2*-induced neurons (n = 3 from two lines). Primer sequences are listed in [Table S3](#mmc1){ref-type="supplementary-material"}.(F) Principal component analysis of lineage-specific marker expression in 23 pairs of hiPSC-astrocytes and isogenic source NPCs, together with four pAstrocyte lines isolated from fetal cerebral cortex, midbrain, cerebellum, and whole brain.(G) Flow-cytometry analysis of S100β (top) and GFAP (bottom) for pAstrocytes from the cerebral cortex, midbrain, cerebellum, and whole brain. Appropriate secondary-only control is shown in black. CC, cerebral cortex; Mid, midbrain; Cereb, cerebellum; Mixed, whole brain; hiPSC-Astros, hiPSC-astrocytes; pAstros, primary human fetal astrocytes.Data are presented as mean ± SD using two-tailed homoscedastic Student\'s t test. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.Table 1Screening Conditions for Astrocyte DifferentiationIDReferenceBasal MediumSupplement 1Supplement 2Growth Factors1[@bib6]DMEM/F12N2, B27GlutaMAX + sodium bicarbonate + sodium pyruvateBDNFGDNFcAMPAA2ScienCell 1801ND (AM)AGS2% FBS3Thermo Fisher A1261301DMEMN2GlutaMAX + D-glucose + sodium pyruvate10% FBS4Lonza CC-3186ND--L-glutamineEGF3% FBSinsulin + AA5C.M.K., unpublished dataneural basal glutamine2× N2FGF2 + CNTF6modified from C.M.K., unpublished dataneural basal glutamineN2, B27GlutaMAX, NEAA, bMEFGF2 + CNTF7[@bib24]DMEM/F12N2, B27GlutaMAX, NEAA, bMEFGF2 + CNTF8[@bib21]DMEM/F12N2, B27GlutaMAX, NEAA, bMEFGF2 + CNTFBMP49reduction of % FBS from no. 10DMEM/F12N2, B27GlutaMAX, NEAA, bMEFGF2 + CNTFBMP43% FBS10[@bib41]DMEM/F12N2, B27GlutaMAX, NEAA, bMEFGF2 + CNTFBMP410% FBS11[@bib46]DMEM/F12N2, B27GlutaMAX, NEAA, bMEFGF2 + CNTFBMP43% FBSneuregulin12adding insulin + AA to no. 9DMEM/F12N2, B27GlutaMAX, NEAA, bMEFGF2 + CNTFBMP43% FBSinsulin + AA[^2]

We next tested the efficacy of this protocol across 42 NPC lines from 30 individuals (including healthy controls as well as cases with schizophrenia and frontotemporal dementia; 16 male and 14 female) generated as part of three unique hiPSC cohorts (reprogrammed and differentiated through different protocols in independent laboratories) ([Table S2](#mmc1){ref-type="supplementary-material"}). All 42 NPC lines ultimately yielded replicative cells with an astrocyte-like morphology (although not necessarily on the first attempt), with an average composition of 90% S100β^+^ and 82% GFAP^+^ cells by flow cytometry, relative to the appropriate secondary antibody control ([Figures 1](#fig1){ref-type="fig"}A and 1B; hiPSCs served as a negative control, lacking S100β- and GFAP-positive cells), and confirmed by immunocytochemistry ([Figures 1](#fig1){ref-type="fig"}A, 1C, [S1](#mmc1){ref-type="supplementary-material"}J, and S1K). As with primary astrocytes ([Figures 1](#fig1){ref-type="fig"}G and [S1](#mmc1){ref-type="supplementary-material"}O), there is substantial variability in mean fluorescent intensity between S100β- and GFAP-positive hiPSC-astrocyte populations ([Figure 1](#fig1){ref-type="fig"}A).

Within 30 days, hiPSC-astrocytes were immunopositive for the astrocyte markers ALDH1L1 ([@bib8]) and Vimentin (VIM) ([@bib43]), as well as the glutamate transporters GLAST (EAAT1 and GLUT1) ([@bib40]) ([Figures 1](#fig1){ref-type="fig"}C, [S1](#mmc1){ref-type="supplementary-material"}L, and S1M). Compared with NPCs or excitatory neurons (h*NGN2*-induced neurons) ([@bib7]), hiPSC-astrocytes expressed *GFAP* ([@bib27]), *S100β* ([@bib27]), *VIM* ([@bib43]), *AQU4* ([@bib19]), *ACSBG1* ([@bib9]), and *APOE* ([@bib4]) by qPCR ([Figure 1](#fig1){ref-type="fig"}D), although expression levels between individual hiPSC-astrocytes and primary astrocyte lines varied substantially. In addition, hiPSC-astrocytes expressed low levels of the neuronal markers *TUJ1*, *MAP2AB*, *RELN*, and *CACNA1C* ([Figure 1](#fig1){ref-type="fig"}E).

Across a larger panel of neural lineage markers ([Table S4](#mmc1){ref-type="supplementary-material"}) in 23 hiPSC-astrocyte lines and their isogenic NPC lines, principal component analysis (PCA) revealed that the NPCs grouped together, while the astrocytes (both hiPSC-derived and primary human fetal astrocytes) were more dispersed ([Figures 1](#fig1){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}N). Because it was apparent in our hiPSC-astrocytes as well as the primary human fetal astrocytes (obtained from different donors and brain regions), this variability in lineage marker expression may reflect inter-individual variability and/or differences in regional patterning ([Figures 1](#fig1){ref-type="fig"}G and [S1](#mmc1){ref-type="supplementary-material"}O).

hiPSC-Astrocytes and Primary Human Fetal Astrocytes Share Similar Transcriptional Profiles {#sec2.2}
------------------------------------------------------------------------------------------

To query the extent to which global gene expression in hiPSC-astrocytes resembles primary human fetal brain astrocytes, we performed RNA sequencing (RNA-seq) transcriptomic analyses on four control hiPSC-astrocytes and primary human fetal astrocytes from two brain regions (cerebral cortex and midbrain), together with isogenic hiPSC-derived NPCs and neurons ([Figures 2](#fig2){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}), comparing them with *in vivo* human and rodent astrocyte transcriptomic datasets ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [S2](#mmc1){ref-type="supplementary-material"}, and [S3](#mmc1){ref-type="supplementary-material"}). hiPSC-astrocytes showed transcriptional profiles most similar to those of fetal brain astrocytes. Using PCA and hierarchical clustering, all four hiPSC-astrocytes clustered together with the primary human fetal astrocytes and distinct from the NPC and neuron clusters ([Figures 2](#fig2){ref-type="fig"}A, 2B, and [S2](#mmc1){ref-type="supplementary-material"}A).Figure 2Transcriptional Profile of hiPSC-Astrocytes and Primary Human Fetal AstrocytesRNA-seq analysis of hiPSC-derived NPCs (n = 8), neurons (n = 6), and astrocytes (n = 4) together with pAstrocytes from human fetal cerebral cortex and midbrain.(A and B) Principal component (P.Co) analysis (A) and clustering diagram (B) of hiPSC-derived NPCs, neurons, and astrocytes, together with pAstrocytes.(C) Volcano plot comparison of hiPSC-astrocytes to pAstrocytes (top), as well as to hiPSC-derived NPCs (middle) and neurons (bottom). Average log~2~(fold change) versus −log~10~(FDR) is shown for all genes. Genes upregulated and downregulated by 2-fold change and FDR \< 0.05 are labeled by red dots. The number of genes differentially expressed between different cell types is indicated by the red color density and quantified in [Figure S2](#mmc1){ref-type="supplementary-material"}B.(D) Scatterplot (left) comparing gene expression in hiPSC-astrocytes and pAstrocytes. r represents the Spearman correlation coefficient. Venn diagram (right) of overlapping gene expression (CPM \> 5) between hiPSC-astrocytes and pAstrocytes.(E) Functional pathway enrichment analysis of differentially expressed genes between hiPSC-astrocytes and pAstrocytes (left), hiPSC-astrocytes and NPCs (middle), and pAstrocytes and NPCs (right); hiPSC-astrocytes and pAstrocytes express increased extracellular cell communication signals, but decreased neuronal signals relative to NPCs.(F) Heatmap produced by Wilcoxon\'s rank-sum comparisons of hiPSC-derived NPCs, neurons, and astrocytes, as well as pAstrocytes, relative to the Allen BrainSpan Atlas.(G) Fold enrichment from functional pathway analysis of astrocyte-enriched genes, group G2 sorted from top 100 most variable genes from [Figure S3](#mmc1){ref-type="supplementary-material"}A and [Table 2](#tbl2){ref-type="table"}.Figure 3Characterization of the Neuroinflammatory Status and Reactivity of hiPSC-Astrocytes(A) Cluster analysis of hiPSC-derived NPCs, neurons, and astrocytes, as well as pAstrocytes, combined with a human adult brain dataset ([@bib58]). hiPSC-Astros, hiPSC-astrocytes; pAstros, primary human fetal astrocytes; FDR, false discovery rate; CPM, counts per million.(B) Cluster diagram of hiPSC-astrocytes and pAstrocytes compared with the astrocyte reactivity dataset ([@bib56]), which was sorted by reactivity genes enriched in the A1 (LPS-treatment), A2 (MCAO ischemia), and pan-reactive phenotypes, or related controls (saline and sham, respectively).(C) IL-6 secretion from pAstrocytes (cerebral cortex, midbrain, cerebellum and whole brain \[mixed regions\]) and negative controls (fibroblasts and NPCs), after 24-hr treatment with 50 ng/mL or 100 ng/mL poly(I:C), 10 μg/mL or 50 μg/mL LPS, or 5 μM or 10 μM Aβ42 and its relative vehicle controls (saline for poly(I:C) and LPS, and Tris-HCl \[pH 8\] for Aβ(1--42)), as measured by ELISA.(D) IL-6 secretion following 24-hr treatment with poly(I:C), LPS, and Aβ42 across hiPSC-astrocyte differentiations from nine NPC lines from three independent hiPSC cohorts. hiPSC-Astros, hiPSC-astrocytes; pAstros, primary human fetal astrocytes.Data are presented as mean ± SD using one-way ANOVA with Tukey multiple comparison test. n.s., not significant; ^∗^p \< 0.05, ^∗∗∗^p \< 0.001.

There were nearly 6-fold fewer differentially expressed genes (DEGs) between hiPSC-astrocytes and primary human fetal astrocytes (900 genes) than between hiPSC-astrocytes and isogenic hiPSC-derived neurons (10,000 genes) or NPCs (5,500 genes) ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}B). hiPSC-astrocytes are highly similar to primary human fetal astrocytes (r = 0.945); the majority of both expressed genes (counts per million \[CPM\] \> 1) and enriched genes (CPM \> 5) were shared between hiPSC-astrocytes and primary human fetal astrocytes (87.0% and 90.3%, respectively) ([Figure 2](#fig2){ref-type="fig"}D). Functional enrichment analyses (using MSigDB) demonstrated that signals regulating neuronal maturation, such as synapse or ion channel formation, were downregulated in hiPSC-astrocytes and primary human fetal astrocytes, whereas signals promoting extracellular cell adhesion and interaction were upregulated ([Figure 2](#fig2){ref-type="fig"}E). When we specifically considered just the top 100 most varying genes distinguishing hiPSC-astrocytes from hiPSC-derived NPCs and neurons, functional enrichment analysis identified a group of 19 genes related to reactivity, cytokine, interferon, T cell receptor (TCR), and antigen-processing signaling that were enriched in astrocytes (G2) ([Figures 3](#fig3){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}C; [Table 2](#tbl2){ref-type="table"}).Table 2Annotation of the Top 100 Most Variable GenesMSigDBGroupOverlap SizeGroup SizeMSigDB SizeFEp ValueFDROverlap GenesAntigen processing and presentationG271957151.31.71 × 10^−14^8.49 × 10^−11^CD74; HLA-DOA; HLA-DQA1; HLA-DQB1; HLA-DRA; HLA-DRB1; HLA-DRB5Cell adhesion molecules (CAMS)G261911564.33.17 × 10^−10^3.61 × 10^−7^HLA-DOA; HLA-DQA1; HLA-DQB1; HLA-DRA; HLA-DRB1; HLA-DRB5Reactome MHC class II antigen presentationG25198671.66.64 × 10^−9^6.94 × 10^−6^CD74; HLA-DOA; HLA-DQA1; HLA-DRB1; HLA-DRB5Reactome translocation of ZAP70 to immunological synapseG231975281.58 × 10^−8^1.53 × 10^−5^HLA-DQA1; HLA-DRB1; HLA-DRB5Reactome phosphorylation of CD3 and TCR ζ chainsG231910369.65.42 × 10^−8^4.85 × 10^−5^HLA-DQA1; HLA-DRB1; HLA-DRB5Reactome PD1 signalingG2319113367.45 × 10^−8^6.22 × 10^−5^HLA-DQA1; HLA-DRB1; HLA-DRB5Reactome generation of second messenger moleculesG231918205.33.67 × 10^−7^0.000287HLA-DQA1; HLA-DRB1; HLA-DRB5Reactome downstream TCR signalingG231927136.91.31 × 10^−6^0.000965HLA-DQA1; HLA-DRB1; HLA-DRB5Neuron differentiationG14287345.81.68 × 10^−6^0.001205CNTN4; LMX1B; OTX2; SLIT1Generation of neuronsG14287942.32.31 × 10^−6^0.001574CNTN4; LMX1B; OTX2; SLIT1Axon guidanceG1328221142.32 × 10^−6^0.001574CNTN4; OTX2; SLIT1NeurogenesisG14288937.63.73 × 10^−6^0.002458CNTN4; LMX1B; OTX2; SLIT1Nervous system developmentG162836613.73.95 × 10^−6^0.002538CNTN4; LMX1B; LY6H; OTX2; SHOX2; SLIT1Reactome TCR signalingG23194190.14.74 × 10^−6^0.002876HLA-DQA1; HLA-DRB1; HLA-DRB5Nervous system developmentS151736618.84.82 × 10^−6^0.002876CNTN4; LMX1B; LY6H; SHOX2; SLIT1Biocarta TCRA pathwayG22195492.86.23 × 10^−6^0.003549HLA-DRA; HLA-DRB1Reactome co-stimulation by the CD28 familyG23195271.19.77 × 10^−6^0.005322HLA-DQA1; HLA-DRB1; HLA-DRB5Reactome interferon-γ signalingG23195764.81.29 × 10^−5^0.006553HLA-DQA1; HLA-DRB1; HLA-DRB5Biocarta IL-5 pathwayG221973521.31 × 10^−5^0.006553HLA-DRA; HLA-DRB1AxonogenesisG13284259.71.71 × 10^−5^0.007939CNTN4; OTX2; SLIT1Biocarta asbcell pathwayG221983081.74 × 10^−5^0.007939HLA-DRA; HLA-DRB1Neuron differentiationS13177356.61.92 × 10^−5^0.00858CNTN4; LMX1B; SLIT1[^3]

To assess the extent to which hiPSC-astrocytes are related to human brain astrocytes *in vivo*, we compared expression profiles of hiPSC-derived astrocytes, NPCs, and neurons from four healthy controls, as well as primary human fetal astrocytes, with the Allen BrainSpan Atlas of the Developing Human Brain (<http://www.brainspan.org>) ([@bib32]) using a Spearman rank correlation analysis. Heatmaps generated through a Wilcoxon\'s rank-sum test revealed that gene expression in hiPSC-astrocytes and primary human fetal astrocytes was highly correlated with gene expression in human fetal cortical brain tissue (8--16 weeks post conception) ([Figure 2](#fig2){ref-type="fig"}F). Unsupervised hierarchical cell-type-specific cluster analysis demonstrated that hiPSC-astrocytes closely cluster with astrocytes purified by immunopanning from human brain tissue, particularly hippocampal astrocytes, rather than oligodendrocytes, endothelial cells, myeloid cells, or neurons ([@bib58]) ([Figure 3](#fig3){ref-type="fig"}A); pathway analysis further revealed that many astrocyte-enriched genes were related to immune signaling ([Figure 2](#fig2){ref-type="fig"}G).

Expression Profile of hiPSC-Astrocytes Resembles Quiescent Astrocytes {#sec2.3}
---------------------------------------------------------------------

To determine whether the gene expression pattern of our control hiPSC-astrocytes more resembles quiescent or reactive astrocytes, we compared them with an RNA-seq dataset of "proinflammatory" A1-type and "immunoregulatory" A2-type murine astrocytes, as well as their saline- and sham-treated controls ([@bib56]). (Because these are *in vivo* cell types, whereby A1-type astrocytes are induced by a bacterial lipopolysaccharide \[LPS\] infection and A2-type astrocytes by middle cerebral artery occlusion \[MCAO\], no comparable dataset exists for human astrocytes.) hiPSC-astrocyte gene expression best clusters with the control conditions ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A), suggesting that hiPSC-astrocytes may be closer to the quiescent state than to reactive astrocytes.

hiPSC-Astrocytes Secrete Cytokines in Response to Inflammatory Stimuli {#sec2.4}
----------------------------------------------------------------------

A key effector of the astrocyte neuroinflammatory response in neurodegenerative diseases is interleukin 6 (IL-6) ([@bib59]). Consistent with effects observed in primary human fetal astrocytes ([Figure 3](#fig3){ref-type="fig"}C), 24-hr treatment with polyinosinic-polycytidylic acid (poly(I:C)) (50 ng/mL or 100 ng/mL), LPS (10 μg/mL or 50 μg/mL), and β-amyloid 42 (Aβ42) (5 μM or 10 μM) led to dose-dependent increases in IL-6 secretion in control hiPSC-astrocytes ([Figure 3](#fig3){ref-type="fig"}D), but not the source hiPSC-derived NPCs ([Figure 3](#fig3){ref-type="fig"}C).

To more fully characterize the release of inflammatory mediators from control hiPSC-astrocytes following 24-hr treatment with 5 μM Aβ42, a main component of the amyloid plaques in AD, we measured proinflammatory (IL-1β, IL-4, IL-6, IL-8, IL-10, and tumor necrosis factor α) and anti-inflammatory cytokines (IL-1α, IL-2, IL-12, IL-17α, interferon-γ, and granulocyte macrophage colony-stimulating factor) by Multi-Analyte ELISArray, confirming that Aβ42 treatment primarily increased IL-6 secretion ([@bib15]), as well as a second proinflammatory cytokine, IL-8 ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). We also measured 36 cytokines, chemokines, and acute-phase proteins using the Proteome Profiler Human Cytokine Array ([Table S5](#mmc1){ref-type="supplementary-material"}) in baseline conditions and following 24-hr treatment with 5 μM Aβ42 ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}C--S3E); Aβ42 increased IL-6 release in both hiPSC-astrocytes and primary human fetal astrocytes ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Together, our findings indicate that hiPSC-astrocytes are capable of secreting proinflammatory cytokines in response to neuroinflammatory cues.

hiPSC-Astrocytes Display Phagocytic Capacity and Promote Phagocytic Function of Microglia {#sec2.5}
-----------------------------------------------------------------------------------------

Astrocytes can phagocytose and degrade β-amyloid in AD ([@bib11], [@bib52]). We used flow cytometry to examine the ability of control hiPSC-astrocytes to phagocytose pHrodo red conjugated myelin or zymosan bioparticles (pHrodo red dye fluoresces red in the acidic environment of phagosomes; zymosan is an agonist of Toll-like receptor 2 \[TLR2\] \[[@bib29], [@bib39]\]). hiPSC-astrocytes, primary human fetal astrocytes, and BV2 microglia showed a similar capacity to internalize myelin purified from brain homogenates, while zymosan bioparticle uptake was much greater in microglia (consistent with higher levels of TLR2 reported in microglia) ([@bib20]) ([Figures 4](#fig4){ref-type="fig"}A, 4B, and [S4](#mmc1){ref-type="supplementary-material"}A--S4C; [Movie S1. Phagocytosis of Myelin in BV2 Microglia](#mmc2){ref-type="supplementary-material"}, [Movie S2. Phagocytosis of Myelin in hiPSC-Astrocytes](#mmc3){ref-type="supplementary-material"}, [Movie S3. Phagocytosis of Myelin in Primary Astrocytes](#mmc4){ref-type="supplementary-material"}). The specificity of bioparticle uptake was confirmed by treating cells with cytochalasin D, an inhibitor of β-actin polymerization that reduces phagocytosis ([Figures 4](#fig4){ref-type="fig"}A and 4B).Figure 4Impact of hiPSC-Astrocytes on the Phagocytic Capacity of BV2 Microglial Cells(A) Phagocytic indices of BV2 cells, hiPSC-astrocytes, and pAstrocytes incubated with 20 μg of pHrodo-labeled myelin for 3 hr and analyzed by flow cytometry.(B) Amnis images representative of pHrodo red myelin after engulfment in hiPSC-astrocytes, pAstrocytes, and BV2 cells.(C) Phagocytic indices of BV2 microglia co-cultured with hiPSC-astrocytes and pAstrocytes that were treated with 30 μg of pHrodo-labeled zymosan for 3 hr and analyzed by flow cytometry, F(3, 33) = 79.33.(D) Phagocytic indices of BV2 microglia treated with astrocyte conditioned medium for 20 hr and then incubated with 30 μg of pHrodo-labeled zymosan for 3 hr for analysis by flow cytometry, F(3, 13) = 30.80. Data are representative of three independent experiments from 6--8 different control hiPSC-astrocytes and 2--4 different pAstrocytes and are shown as mean ± SEM. Similar significance was obtained in two other independent experiments. hiPSC-Astros, hiPSC-astrocytes; pAstros, primary human fetal astrocytes. Treatment with 2 μM cytochalasin D (Cyt) was used as a negative control for phagocytosis inhibition.

Although microglia are the major phagocytic cells in the brain, astrocytes mediate microglial response to inflammatory stimuli ([@bib24], [@bib25], [@bib48]). We repeated the pHrodo red zymosan assay using microglia-astrocyte co-cultures; both hiPSC-astrocytes and primary human fetal astrocytes enhanced phagocytic capacity of BV2 mouse microglial cells ([Figures 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}D). We discriminated microglia and astrocyte phagocytic activity by labeling CD11b- and GFAP-positive cells, respectively ([Figure S4](#mmc1){ref-type="supplementary-material"}E). After 3 hr of labeling, only the CD11b^+^ BV2 microglial cells phagocytosed the pHrodo red zymosan bioparticles ([Figure S4](#mmc1){ref-type="supplementary-material"}E) Finally, we treated BV2 microglial cells with astrocyte conditioned medium (ACM) for 24 hr prior to analyzing their phagocytic capacity; pretreatment of BV2 microglial cells with ACM from either hiPSC-astrocytes or primary human fetal astrocytes significantly increased microglial phagocytic capacity ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}F). Taken together, these findings show that both hiPSC-astrocytes and primary human fetal astrocytes secrete factors that increase the capacity of microglia to phagocytose zymosan bioparticles.

hiPSC-Astrocytes Display Spontaneous Calcium Transient Activity {#sec2.6}
---------------------------------------------------------------

We next evaluated whether control hiPSC-astrocytes exhibit spontaneous calcium transients, as has been described for astrocytes ([@bib51]). We used the calcium indicator Fluo-4AM to monitor calcium signaling under basal conditions and in response to a pulse of extracellular glutamate (3 μM) ([@bib58]). A single pulse of glutamate produced a slow calcium response in both hiPSC-astrocytes and primary human fetal astrocytes ([Figure 5](#fig5){ref-type="fig"}). In addition, some cells exhibited spontaneous calcium spikes, suggesting the presence of a network of connected astrocytes ([@bib42]) ([Figures 5](#fig5){ref-type="fig"}A--5D). To quantify these responses, we measured the frequency of spontaneous activity, the number of spontaneous spikes per time, and the amplitude of the calcium spike ([Figures 5](#fig5){ref-type="fig"}E--5G). There was no statistical difference in the frequency and number of spikes between hiPSC-astrocytes and primary astrocytes. Interestingly, the amplitude of the spontaneous calcium spike was significantly higher in hiPSC-astrocytes compared with primary astrocytes. Taken together, the excitability of hiPSC-astrocytes was largely indistinguishable from that of primary human astrocytes.Figure 5Spontaneous and Glutamate-Responsive Calcium Transients in hiPSC-Astrocytes and Primary Astrocytes(A and C) Representative Fluo-4-stained hiPSC-astrocytes and pAstrocytes. Note similarity in shape of cells.(B and D) Plots of fluorescence (RFUs) versus time for 25 regions of interest from hiPSC-astrocytes and pAstrocytes.(E) Average number of spontaneously active cells per field (318 μm^2^) for hiPSC-astrocytes (n = 22 fields from four different lines) and pAstrocytes (n = 12 fields from three different preparations of cerebral cortex astrocytes). n, the number of fields.(F) Average number of calcium spikes per 348-s trace for hiPSC-astrocytes (n = 22) and pAstrocytes (n = 12).(G) Average amplitude of calcium spike in each 348-s trace for hiPSC-astrocytes (n = 22) and pAstrocytes (n = 12). Peak excludes the amplitude of the glutamate-induced spike. Each point represents the average multiple regions of interest per 318 μm^2^. Line shows mean ± SEM. hiPSC-Astros, hiPSC-astrocytes, pAstros, primary human fetal astrocytes. Using a two-tailed Student\'s t test, n.s., not significant; ^∗∗^p \< 0.05.

Discussion {#sec3}
==========

We screened 11 methods to differentiate hiPSC-derived NPCs into astrocytes, identifying a medium with low FBS (1%--2%) that produces populations of hiPSC-astrocytes within 30 days. Although this is a commercial medium sold for the culture of primary astrocytes, it has not previously been demonstrated to support differentiation of hiPSC to astrocytes. Our method is fast and robust: unlike previous reports, it does not require prolonged culture (∼6 months) or a serial sorting process ([@bib24], [@bib46], [@bib55]). This protocol was evaluated across 42 NPC lines from 30 individuals (16 males and 14 females) generated from three independent hiPSC cohorts ([Table S2](#mmc1){ref-type="supplementary-material"}). We caution that the quality of the starting NPC population is a critical predictor of success and note that for a few particularly intransient NPC lines, starting from very low-passage stocks proved critical to the ultimate successful differentiation of hiPSC-astrocytes. By both fluorescence-activated cell sorting and qPCR, GFAP seems to be a more variable marker of astrocyte fate ([Figures 1](#fig1){ref-type="fig"}A and 1B) and we recommend instead using S100β when evaluating hiPSC-astrocyte populations; moreover, more than any single gene, using panels of markers and/or global transcriptomic analysis more fully reveals the extent of astrocyte patterning of each line. We also suggest that hiPSC-astrocyte response to inflammatory stimuli might represent a simple and easy platform by which to confirm the functionality of hiPSC-astrocytes; astrocytes undergo stimulation-dependent cytokine secretion, while NPCs do not secrete cytokines.

To our knowledge, our method is distinct from others recently reported ([@bib10], [@bib16], [@bib21], [@bib24], [@bib30], [@bib45], [@bib46]), its major advantage being the ease by which hiPSC-astrocytes can be concurrently differentiated from many NPCs from multiple individuals, owing to the simplicity of the protocol, and furthermore that astrocytes can be expanded for months and cryopreserved, serving as a source of cells to support an array of experiments. Therefore, because our protocols for NPC and astrocyte culture are robust and easily scaled, this methodology is both preferable for large case-control studies from dozens of idiopathic patients and highly amenable to automated culture and future high-throughput drug screens using patient-derived astrocytes ([@bib54]).

We have established a platform for querying astrocyte-specific contributions to disease predisposition in hiPSC-based models. hiPSC-astrocytes closely resemble primary human fetal astrocytes, purified adult brain astrocytes ([@bib58]), and brain tissue homogenate ([@bib32]) ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}A). Although the transcriptional profile of our hiPSC-astrocytes most closely resembles a quiescent state ([Figure 3](#fig3){ref-type="fig"}B), hiPSC-astrocytes secrete various cytokines and chemokines in response to neuroinflammatory stimuli ([Figures 3](#fig3){ref-type="fig"}C and 3D). hiPSC-astrocytes displayed phagocytic capacity ([Figure 4](#fig4){ref-type="fig"}A) and enhanced the phagocytic function of microglia in a co-culture assay ([Figure 4](#fig4){ref-type="fig"}C). They also showed spontaneous calcium transient activity and responses to glutamate stimulus ([Figure 5](#fig5){ref-type="fig"}). Moreover, because nearly pure populations of excitatory neurons and astrocytes from the same individual, hiPSC clone, and even NPC batch can now be compared, our protocol may reduce experimental variation in studies of the cell-autonomous and non-cell-autonomous factors underlying disease predisposition.

While many studies of neurodegeneration and synaptic dysfunction use either primary mouse or human fetal glia for human neuron co-culture ([@bib22], [@bib23], [@bib50]), these methods are limited by species-specific differences in astrocyte functions and limited access to human fetal samples. Our hiPSC-astrocytes overcome these drawbacks, making possible hiPSC-based astrocyte-neuron ([@bib21]) and astrocyte-microglia ([@bib33], [@bib36]) co-culture platforms for uncovering disease-related mechanisms *in vitro*, which should help to reveal how the crosstalk between these three neural cell types contributes to neurological and psychiatric disease.

Experimental Procedures {#sec4}
=======================

Human subject work on these de-identified control hiPSCs was approved by the Institutional Review Board at Icahn School of Medicine at Mount Sinai. Control mouse brain tissue was obtained from the Center for Comparative Medicine and Surgery at Icahn School of Medicine at Mount Sinai.

NPCs and Astrocyte Cell Culture {#sec4.1}
-------------------------------

Forebrain NPCs were maintained at high density, grown on Matrigel (BD Bioscience) in NPC medium (DMEM/F12, 1× N2, 1× B27-RA \[Invitrogen\], 1 mg/mL laminin \[Invitrogen\], and 20 ng/mL FGF2 \[Invitrogen\]), and split approximately 1:3 to 1:4 every week with Accutase (Millipore). NPCs could be expanded up to 14 passages. Forebrain NPCs were differentiated to astrocytes by seeding dissociated single cells at 15,000 cells/cm^2^ density on Matrigel-coated plates in astrocyte medium (ScienCell: 1801, astrocyte medium \[1801-b\], 2% fetal bovine serum \[0010\], astrocyte growth supplement \[1852\] and 10 U/mL penicillin/streptomycin solution \[0503\]). Initial NPC quality, seeding density, and single-cell dissociation are critical, particularly during the first 30 days of differentiation, in order to efficiently generate hiPSC-astrocytes. See detailed protocol for astrocyte differentiation from hiPSC-derived NPCs in the [Supplemental Information](#app3){ref-type="sec"}.

Immunocytochemistry {#sec4.2}
-------------------

Cultures were washed with PBS and fixed using 4% paraformaldehyde (no. 15714, Electron Microscopy Sciences) for 20 min, then washed three times with PBS 1× plus 0.01% Triton X-100 prior to preincubation with blocking solution made of PBS 1× plus 0.01% Triton X-100 and 10% donkey serum (Sigma-Aldrich), for at least 1 hr. Cultures were then incubated in primary antibody solution overnight at 4°C, followed by an incubation with secondary antibodies for 1 hr at room temperature. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for antibody details and confocal microscopy.

Real-Time qPCR {#sec4.3}
--------------

The total RNA was extracted from cultured cells with an RNeasy mini kit (no. 74106, Qiagen) and reverse transcribed into cDNA with an iScript cDNA Synthesis kit (no. 1708890, Bio-Rad). cDNA was used as template for the qPCR using a 7900 Real-Time PCR system (Applied Biosystems) with Power SYBR Green PCR Master Mix. The primers used are listed in [Table S3](#mmc1){ref-type="supplementary-material"}. Gene expression was analyzed using the ΔΔCt method. All results were normalized to *GAPDH*, *β-ACTIN*, and *TBP* (TATA-box binding protein) expression, and the values of uninduced fibroblasts were set to 1. Three replicates were used to determine the error bars. See the [Supplemental Information](#app3){ref-type="sec"} for RNA expression studies for qRT-PCR and primer sequences.

Analysis of RNA-Seq Data {#sec4.4}
------------------------

Pair-ended RNA-seq data was generated using the Illumina HiSeq 2500 platform for hiPSC-astrocytes (four lines), neurons (six lines), and NPCs (eight lines) ([Table S2](#mmc1){ref-type="supplementary-material"}), as well as for two primary astrocyte samples. The pair-ended sequencing reads were aligned to human hg19 genome using Star Aligner (version 2.5.0b). Following read alignment, featureCounts ([@bib26]) was used to quantify the gene expression at the gene level based on Ensembl gene model GRCh37.70. Gene expression data preprocessing and downstream analyses, including differential gene expression and functional enrichment, are detailed in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

IL-6 ELISA, Multi-Analyte ELISArray, and Protein Array {#sec4.5}
------------------------------------------------------

hiPSC-astrocytes and primary astrocytes were seeded in astrocyte medium 1 day before the experiment. Cells were treated for 24 hr with 50 ng/mL or 100 ng/mL of poly(I:C) (InvivoGen, no. tlrl-pic), 10 μg/mL or 50 μg/mL of LPS (Sigma-Aldrich, no. L5886), and 5 μM or 10 μM human β-amyloid (Aβ42) (CaliforniaPeptide, no. 641-15) and vehicle control solutions (saline for poly(I:C) and LPS or Tris-HCl for Aβ42). Samples were analyzed with IL-6 ELISA assay (Affymetrix eBioscience, no. 88-7066), Human Inflammatory Cytokines Multi-Analyte ELISArray (Qiagen, no. MEH-004A), RT2 Profiler PCR Arrays (Qiagen), and Proteome Profiler Human Cytokine Array (R&D Systems, no. ARY005B). For a detailed protocol see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Phagocytosis Assay {#sec4.6}
------------------

Phagocytic capacity of hiPSC-astrocytes, primary astrocytes, and BV2 cells was analyzed by incubating cells with pHrodo-labeled zymosan (Thermo Fisher, P35364) or myelin purified from mouse brains, and then measured by flow cytometry. Detailed protocols for co-culture experiments and astrocyte conditioned media treatment are provided in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Calcium Imaging {#sec4.7}
---------------

Cells were incubated with 2  μM Fluo-4AM (Molecular Probes) and 0.02% Pluronic F 127 detergent in Krebs HEPES buffer (KHB). Time-lapse image sequences (×40 magnification) were acquired at 0.9 Hz and analyzed by FluoroSNNAP software operated by MATLAB. For a detailed protocol see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analysis {#sec4.8}
--------------------

For all experiments, data are represented as mean ± SD or SEM of three to five biological replicates. Statistical significance was determined using a two-tailed homoscedastic Student\'s t test or one-way ANOVA and Tukey-Kramer post hoc test for differences of means between each group of data with parametric distribution. Significant comparisons are labeled in the figures as ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001.

Extended experimental procedures and any associated references are available in the online version of this paper.
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[^2]: The 11 screened conditions of astrocyte differentiation from hiPSCs, including 3 commercially available astrocyte media (nos. 2--4) and 8 conditions modified from published protocols (nos. 5--12), with a forebrain neuron differentiation protocol (no. 1). NEAA, non-essential amino acid; bME, 2-mercaptoethanol; AA, ascorbic acid; ND, non-disclosure; AM, astrocyte medium; AGS, astrocyte growth supplement.

[^3]: MSigDB (<http://software.broadinstitute.org/gsea/msigdb>) is a collection of gene annotations, including gene ontology, and functional pathways. Overlap size: the number of genes shared between a query gene set (e.g., genes in group 1, G1) and a gene set in MSigDB (e.g., antigen processing and presentation). Group size: the number of genes in a query gene set. MSigDB size: the number of genes in MSigDB gene set. FE, fold enrichment; FDR, false discovery rate.
